IL17A and inflammatory response: The treatment of anti-IL-23p19 diminishes the serum level of IL-17 as well as the expression of IFN-γ, IP-10, IL-17, IL-6, and TNF in the CNS, thus inhibiting multiple inflammatory signaling pathways that drive CNS autoimmune inflammation.